Theravance Biopharma, Inc. (TBPH) announced that Viatris Inc. has secured regulatory approval from China's National Medical Products Administration for YUPELRI inhalation solution, the first once-daily nebulized long-acting muscarinic antagonist approved for maintenance treatment of chronic obstructive pulmonary disease in China.
The approval triggers a one-time $7.5 million milestone from Viatris to Theravance, which is expected to be received in third quarter, 2025. Theravance Biopharma is also eligible for further sales-based milestones of up to $37.5 million and tiered royalties of 14% to 20% on net sales in China.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.